Introduction

Abstract

Prostate cancer continues to increase in incidence in both the developed and the developing world. As population awareness increases in parallel and ready access to diagnostic tests such as serum PSA increases in prevalence, the majority of cases are now diagnosed as localized disease in the low- to intermediate-risk groups. These patients are presented with a bewildering array of possible treatment options, all valid approaches seeking to control or eradicate the cancer whilst inflicting few or no side effects. Amongst these, brachytherapy has emerged as a popular choice with now proven efficacy and a very favourable toxicity profile.